Biohaven Ltd. Interest Income, Other
Biohaven Ltd. (BHVN) reported Interest Income, Other of $1.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-10
- Biohaven Ltd. interest income, other for the quarter ending 2026-06-30 was $1.47M, a 30.84% increase year-over-year.
- Biohaven Ltd. interest income, other for the quarter ending 2026-03-31 was $1.71M, a 69.54% increase year-over-year.
- Biohaven Ltd. interest income, other for the quarter ending 2025-12-31 was $1.65M, a 111.00% increase year-over-year.
- Biohaven Ltd. interest income, other for the quarter ending 2025-09-30 was $1.30M, a 29.78% decline year-over-year.
- Biohaven Ltd. interest income, other for fiscal 2025 was $5.08M, a 27.75% decline from fiscal 2024.
- Biohaven Ltd. interest income, other for fiscal 2024 was $7.03M, a 5.36% decline from fiscal 2023.
- Biohaven Ltd. interest income, other for fiscal 2023 was $7.43M, a 317.29% increase from fiscal 2022.
- Biohaven Ltd. interest income, other for fiscal 2022 was $1.78M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.47M 10-Q · filed 2026-08-10 | $3.18M 10-Q · filed 2026-08-10 | $4.83M derived: sum of 3 quarters · filed 2026-08-10 | $6.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.71M 10-Q · filed 2026-05-04 | $3.36M derived: sum of 2 quarters · filed 2026-05-04 | $4.66M derived: sum of 3 quarters · filed 2026-05-04 | $5.79M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.95M derived: sum of 2 quarters · filed 2026-03-02 | $4.07M derived: sum of 3 quarters · filed 2026-08-10 | $5.08M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.30M 10-Q · filed 2025-11-10 | $2.42M derived: sum of 2 quarters · filed 2026-08-10 | $3.43M 10-Q · filed 2025-11-10 | $4.21M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.12M 10-Q · filed 2026-08-10 | $2.13M 10-Q · filed 2026-08-10 | $2.92M derived: sum of 3 quarters · filed 2026-08-10 | $4.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.01M 10-Q · filed 2026-05-04 | $1.79M derived: sum of 2 quarters · filed 2026-05-04 | $3.64M derived: sum of 3 quarters · filed 2026-05-04 | $5.78M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.63M derived: sum of 2 quarters · filed 2026-03-02 | $4.77M derived: sum of 3 quarters · filed 2026-03-02 | $7.03M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-10 | $3.99M derived: sum of 2 quarters · filed 2025-11-10 | $6.25M 10-Q · filed 2025-11-10 | $9.41M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.14M 10-Q · filed 2025-08-11 | $4.40M 10-Q · filed 2025-08-11 | $7.56M derived: sum of 3 quarters · filed 2026-03-02 | $9.11M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $2.26M 10-Q · filed 2025-05-12 | $5.42M derived: sum of 2 quarters · filed 2026-03-02 | $6.97M derived: sum of 3 quarters · filed 2026-03-02 | $8.91M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.71M derived: sum of 2 quarters · filed 2026-03-02 | $6.65M derived: sum of 3 quarters · filed 2026-03-02 | $7.43M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.55M 10-Q · filed 2024-11-12 | $3.49M derived: sum of 2 quarters · filed 2024-11-12 | $4.28M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.94M 10-Q · filed 2024-08-09 | $2.73M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $786.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.78M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |